Renalytix (LON:RENX) Trading Up 18.5% – Should You Buy?

Renalytix Plc (LON:RENXGet Free Report) was up 18.5% during mid-day trading on Friday . The stock traded as high as GBX 3.90 and last traded at GBX 3.85. 2,615,687 shares changed hands during trading, an increase of 197% from the average daily volume of 881,370 shares. The stock had previously closed at GBX 3.25.

Renalytix Trading Up 18.5%

The stock has a market cap of £16.83 million, a P/E ratio of -0.96 and a beta of 1.81. The firm’s 50 day simple moving average is GBX 2.36 and its two-hundred day simple moving average is GBX 2.84. The company has a quick ratio of 2.42, a current ratio of 1.57 and a debt-to-equity ratio of -483.33.

About Renalytix

(Get Free Report)

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).

See Also

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.